-
公开(公告)号：US20130079280A1
公开(公告)日：2013-03-28
申请号：US13640057
申请日：2011-04-12
申请人： Manuel Baca , Thomas Thisted , Jeffrey Swers
发明人： Manuel Baca , Thomas Thisted , Jeffrey Swers
IPC分类号： C07K19/00
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/001 , C07K14/78 , C07K16/1027 , C07K16/2878 , C07K16/468 , C07K2317/73 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.
摘要翻译： 本发明提供了特异性结合一种或多种特异性靶抗原的基于纤连蛋白III（Fn3）的多聚体支架。 本发明还提供了同时结合两种或多种靶抗原的双特异性Fn3衍生结合分子，融合物，缀合物和增加Fn3基结合分子稳定性的方法。 此外，本发明涉及含有Fn3的多聚体支架的预防，治疗或诊断试剂。
-
公开(公告)号：US09212231B2
公开(公告)日：2015-12-15
申请号：US13639381
申请日：2011-04-12
申请人： Manuel Baca , Thomas Thisted , Jeffrey Swers , David Tice
发明人： Manuel Baca , Thomas Thisted , Jeffrey Swers , David Tice
IPC分类号： C07K19/00 , C07K14/47 , C07K14/78 , C07K16/10 , C07K16/28 , C07K16/46 , C07K14/00 , C07K14/715 , A61K39/00
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/001 , C07K14/78 , C07K16/1027 , C07K16/2878 , C07K16/468 , C07K2317/73 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
摘要翻译： 本发明提供特异性结合参与凋亡的细胞膜受体TRAIL受体2（TRAIL R2）的基于腱生蛋白-3 FnIII结构域的多聚体支架。 本发明进一步提供了对目标具有增加的亲和力，增加的稳定性和降低的免疫原性的工程改造的变体。 此外，本发明涉及作为预防，诊断或治疗剂的工程化多价支架，以及它们对由表达TRAIL R2的细胞引起的疾病的用途，特别是抗癌治疗用途的用途。
-
公开(公告)号：US20130096058A1
公开(公告)日：2013-04-18
申请号：US13639381
申请日：2011-04-12
申请人： Manuel Baca , Thomas Thisted , Jeffrey Swers , David Tice
发明人： Manuel Baca , Thomas Thisted , Jeffrey Swers , David Tice
IPC分类号： C07K14/00
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/001 , C07K14/78 , C07K16/1027 , C07K16/2878 , C07K16/468 , C07K2317/73 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
摘要翻译： 本发明提供特异性结合参与凋亡的细胞膜受体TRAIL受体2（TRAIL R2）的基于腱生蛋白-3 FnIII结构域的多聚体支架。 本发明进一步提供了对目标具有增加的亲和力，增加的稳定性和降低的免疫原性的工程改造的变体。 此外，本发明涉及作为预防，诊断或治疗剂的工程化多价支架，以及它们对由表达TRAIL R2的细胞引起的疾病的用途，特别是抗癌治疗用途的用途。
-
公开(公告)号：US20100298541A1
公开(公告)日：2010-11-25
申请号：US12739149
申请日：2008-10-31
申请人： Herren Wu , Manuel Baca , Jeffrey Swers , Benoy Chacko
发明人： Herren Wu , Manuel Baca , Jeffrey Swers , Benoy Chacko
IPC分类号： C07K14/00
CPC分类号： G01N33/566 , C07K14/78 , C07K16/2878 , C07K2318/20 , C07K2319/00 , C12N15/1037 , C12N15/1044
摘要： The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
摘要翻译： 本发明提供蛋白质支架和制备，筛选，工程和使用这种蛋白质支架的方法。
-
公开(公告)号：US08633297B2
公开(公告)日：2014-01-21
申请号：US12739149
申请日：2008-10-31
申请人： Herren Wu , Manuel Baca , Jeffrey Swers , Benoy Chacko
发明人： Herren Wu , Manuel Baca , Jeffrey Swers , Benoy Chacko
CPC分类号： G01N33/566 , C07K14/78 , C07K16/2878 , C07K2318/20 , C07K2319/00 , C12N15/1037 , C12N15/1044
摘要： The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
摘要翻译： 本发明提供蛋白质支架和制备，筛选，工程和使用这种蛋白质支架的方法。
-
6.发明申请公开(公告)号：US20100285035A1
公开(公告)日：2010-11-11
申请号：US12774966
申请日：2010-05-06
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P35/00 , A61P1/00 , A61P17/06 , A61P11/06 , A61P37/08 , A61P29/00 , A61P17/00 , C12N15/60 , C12N5/10
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
7.发明授权Oxidation of propane to give acrylic acid using catalysts in a mixture of crystalline phases 失效使用催化剂在结晶相的混合物中氧化丙烷以产生丙烯酸公开(公告)号：US07683213B2
公开(公告)日：2010-03-23
申请号：US10558023
申请日：2004-05-25
申请人： Jean-Luc Dubois , Manuel Baca , Jean-Marc Millet
发明人： Jean-Luc Dubois , Manuel Baca , Jean-Marc Millet
IPC分类号： C07C51/16
CPC分类号： B01J23/28 , B01J23/002 , B01J23/18 , B01J23/20 , B01J27/0576 , B01J35/0006 , B01J2523/00 , C07C51/215 , C07C57/04 , B01J2523/55 , B01J2523/56 , B01J2523/64 , B01J2523/68 , B01J2523/53
摘要： The invention relates to a method for the production of acrylic acid from propane, in which a gas mixture comprising propane, water vapour and, optionally, an inert gas and/or molecular oxygen is passed over a catalyst, comprising a crystalline catalyst phase of formula (I) or (I′) TeaMolVbNbcOx (I) Sba Mol VbOy (I′), associated with a crystalline catalyst phase for activating the propane.
摘要翻译： 本发明涉及一种从丙烷生产丙烯酸的方法，其中将包含丙烷，水蒸汽和任选的惰性气体和/或分子氧的气体混合物通过催化剂，该催化剂包含式 （I）或（I'）TeaMolVbNbcOx（I）Sba Mol VbOy（I'），与用于活化丙烷的结晶催化剂相关。
-
公开(公告)号：US07517959B2
公开(公告)日：2009-04-14
申请号：US11598212
申请日：2006-11-09
申请人： Raymond Stanley Norton , Jeffrey James Babon , Sandra Elaine Nicholson , Nicos Anthony Nicola , Edward James McManus , Manuel Baca , Shenggen Yao
发明人： Raymond Stanley Norton , Jeffrey James Babon , Sandra Elaine Nicholson , Nicos Anthony Nicola , Edward James McManus , Manuel Baca , Shenggen Yao
CPC分类号： C07K14/4703 , A61K38/17
摘要： The present invention relates to the identification of a PEST motif in Suppressor of Cytokine Signalling (SOCS) proteins, the deletion/inactivation of which has been found to increase the stability of the protein whilst maintaining at least one biological activity of the protein. Such SOCS proteins with deleted/inactivated PEST motifs can be used in gene and protein therapy procedures to provide a more stable SOCS protein when compared to the native protein. The present invention also relates to the characterization of the structure of SOCS proteins, and methods of using this structural information to identify compounds which modulate the activity of SOCS.
摘要翻译： 本发明涉及鉴定细胞因子信号传导抑制因子（SOCS）蛋白质的抑制因子的PEST基序，已经发现其缺失/失活增加了蛋白质的稳定性，同时保持蛋白质的至少一种生物学活性。 具有缺失/失活的PEST基序的这种SOCS蛋白质可用于基因和蛋白质治疗程序，以便与天然蛋白质相比提供更稳定的SOCS蛋白质。 本发明还涉及SOCS蛋白质结构的表征，以及使用该结构信息鉴定调节SOCS活性的化合物的方法。
-
9.发明申请公开(公告)号：US20080166343A1
公开(公告)日：2008-07-10
申请号：US11875017
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US06884879B1
公开(公告)日：2005-04-26
申请号：US08908469
申请日：1997-08-06
申请人： Manuel Baca , James A. Wells
发明人： Manuel Baca , James A. Wells
CPC分类号： C07K16/22 , A61K38/00 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/569 , C07K2317/73
摘要： Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
摘要翻译： 公开了人源化和变异的抗VEGF抗体及其各种用途。 抗VEGF抗体对VEGF具有很强的结合亲和力; 体外抑制VEGF诱导的内皮细胞增殖; 并在体内抑制肿瘤生长。
-
-
-
-
-
-
-
-
-
搜索结果
46 条记录 (耗时 0.036 秒)